Ottesen

Ottesen v. Hi-Tech Pharmaceuticals, Inc.

Good Law
United States District Court, Northern District of CaliforniaFebruary 13, 20244:19-cv-07271California2,455 words

Opinion

Trial Court Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 ALLISON OTTESEN, et al., Case No. 19-cv-07271-JST

Plaintiffs,

ORDER GRANTING MOTION TO

v. CERTIFY ORDER FOR

INTERLOCUTORY APPEAL AND

HI-TECH PHARMACEUTICALS, INC., MOTION TO STAY PENDING

APPEAL

Defendant. 11 Re: ECF No. 75 12 Before the Court is Defendant Hi-Tech’s motion to certify the Court’s October 17, 2023 order lifting the stay of the case for interlocutory appeal and motion to stay pending appeal. ECF No. 75. The Court will grant the motions. I. BACKGROUND Because the facts are well-known to the parties and the Court has summarized Plaintiffs’ allegations in detail in its prior orders, ECF Nos. 41, 70, the Court will not elaborate them here. In sum, this case concerns the alleged use of DMHA1 in supplements manufactured, distributed, and sold by Defendant Hi-Tech Pharmaceuticals, Inc. On November 20, 2020, the Court stayed the case on primary jurisdiction grounds, “pending a determination by the FDA regarding the…

Sign in to read the full opinion

Create a free account to read the complete opinion text, citation history, and good-law status for this case.